Evans, Jennifer S., Wu, Guanghui, Selden, David, Buczkowski, Hubert, Thorne, Leigh, Fooks, Anthony R. and Banyard, Ashley C. (2018) Utilisation of chimeric lyssaviruses to assess vaccine protection against highly divergent lyssaviruses. Viruses , 10 (3). 130. doi:10.3390/v10030130 ISSN 1999-4915.

Preview

PDF WRAP-utilisation-chimeric-lyssaviruses-vaccine-protection-Evans-2018.pdf - Published Version - Requires a PDF viewer. Available under License Creative Commons Attribution 4.0. Download (1482Kb) | Preview

Request Changes to record.

Abstract

Lyssaviruses constitute a diverse range of viruses with the ability to cause fatal encephalitis known as rabies. Existing human rabies vaccines and post exposure prophylaxes (PEP) are based on inactivated preparations of, and neutralising antibody preparations directed against, classical rabies viruses, respectively. Whilst these prophylaxes are highly efficient at neutralising and preventing a productive infection with rabies virus, their ability to neutralise other lyssaviruses is thought to be limited. The remaining 15 virus species within the lyssavirus genus have been divided into at least three phylogroups that generally predict vaccine protection. Existing rabies vaccines afford protection against phylogroup I viruses but offer little to no protection against phylogroup II and III viruses. As such, work involving sharps with phylogroup II and III must be considered of high risk as no PEP is thought to have any effect on the prevention of a productive infection with these lyssaviruses. Whilst rabies virus itself has been characterised in a number of different animal models, data on the remaining lyssaviruses are scarce. As the lyssavirus glycoprotein is considered to be the sole target of neutralising antibodies we generated a vaccine strain of rabies using reverse genetics expressing highly divergent glycoproteins of West Caucasian Bat lyssavirus and Ikoma lyssavirus. Using these recombinants, we propose that recombinant vaccine strain derived lyssaviruses containing heterologous glycoproteins may be a suitable surrogate for wildtype viruses when assessing vaccine protection for the lyssaviruses.

Item Type:	Journal Article
Subjects:	Q Science > QR Microbiology > QR355 Virology
Divisions:	Faculty of Science, Engineering and Medicine > Science > Life Sciences (2010- )
SWORD Depositor:	Library Publications Router
Library of Congress Subject Headings (LCSH):	Rabies virus, Rabies, Rabies vaccines, Viral antibodies
Journal or Publication Title:	Viruses
Publisher:	MDPI AG
ISSN:	1999-4915
Official Date:	15 March 2018
Dates:	Date Event 15 March 2018 Published 13 March 2018 Accepted
Volume:	10
Number:	3
Article Number:	130
DOI:	10.3390/v10030130
Status:	Peer Reviewed
Publication Status:	Published
Reuse Statement (publisher, data, author rights):	** From PubMed via Jisc Publications Router. ** History: received 02-03-2018; revised 13-03-2018; accepted 13-03-2018.
Access rights to Published version:	Open Access (Creative Commons)
Date of first compliant deposit:	15 May 2018
Date of first compliant Open Access:	15 May 2018
RIOXX Funder/Project Grant:	Project/Grant ID RIOXX Funder Name Funder ID SE0426 Department for Environment, Food and Rural Affairs http://dx.doi.org/10.13039/501100000277 SE0431 Department for Environment, Food and Rural Affairs http://dx.doi.org/10.13039/501100000277 RABYD-VAX Grant Agreement No. 733176 Horizon 2020 Framework Programme http://dx.doi.org/10.13039/100010661

Request changes or add full text files to a record

Repository staff actions (login required)

View Item

Downloads